X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with ALEMBIC LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs ALEMBIC LTD - Comparison Results

ALEMBIC LTD 
   Change

Alembic Limited, in its 99 years of existence, has evolved from being a tincture manufacturer to one of the prominent indigenous pharma companies in India. It is among the top players in the macrolides (anti-infective) and anti-microbials (animal hea... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES ALEMBIC LTD VENUS REMEDIES/
ALEMBIC LTD
 
P/E (TTM) x -9.7 59.1 - View Chart
P/BV x 0.2 3.3 4.5% View Chart
Dividend Yield % 0.0 0.3 -  

Financials

 VENUS REMEDIES   ALEMBIC LTD
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-17
ALEMBIC LTD
Mar-16
VENUS REMEDIES/
ALEMBIC LTD
5-Yr Chart
Click to enlarge
High Rs14353 270.5%   
Low Rs6529 221.8%   
Sales per share (Unadj.) Rs324.24.7 6,868.7%  
Earnings per share (Unadj.) Rs6.48.8 73.1%  
Cash flow per share (Unadj.) Rs40.69.0 450.7%  
Dividends per share (Unadj.) Rs00.15 0.0%  
Dividend yield (eoy) %00.4 0.0%  
Book value per share (Unadj.) Rs366.027.7 1,319.9%  
Shares outstanding (eoy) m12.34267.03 4.6%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.38.7 3.7%   
Avg P/E ratio x16.24.7 346.4%  
P/CF ratio (eoy) x2.64.6 56.2%  
Price / Book Value ratio x0.31.5 19.2%  
Dividend payout %01.7 0.0%   
Avg Mkt Cap Rs m1,28210,962 11.7%   
No. of employees `0000.9NA-   
Total wages/salary Rs m251238 105.5%   
Avg. sales/employee Rs Th4,430.1NM-  
Avg. wages/employee Rs Th278.0NM-  
Avg. net profit/employee Rs Th87.6NM-  
INCOME DATA
Net Sales Rs m4,0001,260 317.4%  
Other income Rs m23264 8.6%   
Total revenues Rs m4,0231,524 264.0%   
Gross profit Rs m78583 947.7%  
Depreciation Rs m42261 686.6%   
Interest Rs m3440 114,566.7%   
Profit before tax Rs m42285 14.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m02,096 0.0%   
Extraordinary Inc (Exp) Rs m0-32 0.0%   
Tax Rs m-376 -606.6%   
Profit after tax Rs m792,343 3.4%  
Gross profit margin %19.66.6 298.6%  
Effective tax rate %-87.92.1 -4,104.7%   
Net profit margin %2.0185.9 1.1%  
BALANCE SHEET DATA
Current assets Rs m2,6061,689 154.3%   
Current liabilities Rs m1,980486 407.3%   
Net working cap to sales %15.695.4 16.4%  
Current ratio x1.33.5 37.9%  
Inventory Days Days128217 59.1%  
Debtors Days Days4381 53.2%  
Net fixed assets Rs m5,3531,624 329.6%   
Share capital Rs m123534 23.1%   
"Free" reserves Rs m4,3935,960 73.7%   
Net worth Rs m4,5167,404 61.0%   
Long term debt Rs m1,618104 1,551.5%   
Total assets Rs m8,2918,010 103.5%  
Interest coverage x1.1950.7 0.1%   
Debt to equity ratio x0.40 2,543.6%  
Sales to assets ratio x0.50.2 306.7%   
Return on assets %5.129.3 17.4%  
Return on equity %1.831.6 5.5%  
Return on capital %6.331.3 20.1%  
Exports to sales %02.9 0.0%   
Imports to sales %18.428.9 63.8%   
Exports (fob) Rs mNA37 0.0%   
Imports (cif) Rs m736364 202.5%   
Fx inflow Rs m037 0.0%   
Fx outflow Rs m736365 201.8%   
Net fx Rs m-736-328 224.6%   
CASH FLOW
From Operations Rs m997346 288.5%  
From Investments Rs m-461-48 969.1%  
From Financial Activity Rs m-571-301 189.7%  
Net Cashflow Rs m-35-3 1,170.0%  

Share Holding

Indian Promoters % 32.9 64.0 51.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 0.2 90.0%  
FIIs % 0.6 9.7 6.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 26.1 254.4%  
Shareholders   20,121 54,701 36.8%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   MERCK LTD  STERLING BIOTECH  ASTRAZENECA PHARMA  AUROBINDO PHARMA  IPCA LABS  

Compare VENUS REMEDIES With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens 99 Points Down; Vedanta & Coal India Top Losers(09:30 am)

Asian share markets are lower today as Japanese and Hong Kong shares fall. The Nikkei 225 is off 0.9% while the Hang Seng is down 2%. The Shanghai Composite is trading down by 2.7%.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (4QFY18); Net Profit Down 307.2%

Jun 12, 2018 | Updated on Jun 12, 2018

For the quarter ended March 2018, VENUS REMEDIES has posted a net profit of Rs 94 m (down 307.2% YoY). Sales on the other hand came in at Rs 932 m (up 16.8% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Should You Get out of Small Caps Now... Before the Fall Worsens(Profit Hunter)

Jun 6, 2018

An almost zero-loss strategy that works best when markets correct. Don't let the current volatility overwhelm you. Focus on the fundamentals and long term, and buy stocks where quality meets value.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Jun 19, 2018 10:33 AM

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 5-YR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS